A Study of Eloralintide in Participants With Obesity, or Overweight Without Type 2 Diabetes
About this study
Are you struggling with obesity or being overweight?
The purpose of this study is to find out whether an experimental medication helps people living with obesity to lose weight.
The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase.
Participation in the main phase of the study will last about 75 weeks. Participants with prediabetes will continue in the extension phase for another 2 years.
Would you like to take part?
As a volunteer in a research study, you’ll receive study-related medical care from the study doctor and regular follow-up of your health to monitor the effectiveness of the care you’ll receive. The results of this research will be used to find out if the investigational medication being studied will be of benefit to others struggling with obesity and weight loss, and whether it will be made widely available to all Canadians trying to manage obesity. Study volunteers are an important part of moving medical care forward.
Who may qualify
- Have Body Mass Index (BMI) at screening of the following:
- 30 kilogram per square meter (kg/m2) OR
- 27 kg/m2 with at least one of the following weight-related health conditions at screening:
- high blood pressure
- dyslipidemia
- obstructive sleep apnea, or
- heart disease
- Have had a stable body weight (<5% body weight change) for 90 days prior to screening.
- Have a history of at least one self-reported unsuccessful dietary effort to reduce body weight.
- Have had a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening)
- Have had a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
- Have type 1 diabetes or type 2 diabetes
- Have had within 90 days prior to screening:
- heart attack
- stroke
- coronary artery revascularization
- unstable angina, or
- hospitalization due to congestive heart failure
- Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure
- Have taken medications or alternative remedies intended for weight loss within 90 days of screening.
What participation may involve
- Regular visits with the study team at no cost
- Study assessments and health monitoring throughout
- Check-ins between visits
- Informed consent before anything begins — questions welcome
What participants may receive
- Study-related care from a physician-led team
- Study assessments at no cost
- Reimbursement for reasonable travel, where applicable
Where this study is enrolling
Learn more
Weight Conditions (Overweight, Obesity)
Obesity is a long-term medical condition in which extra body fat builds up to a point where it can affect health. Canadian clinical guidelines describe it as a…
Read about this condition →General Health
General health is the part of clinical research that is not built around a single diagnosis: prevention, vaccines, healthy ageing, weight and smoking, and studies that need volunteers…
Read about this condition →Diabetes
Diabetes means the level of sugar, or glucose, in your blood stays too high because your body cannot make enough insulin or cannot use the insulin it makes.…
Read about this condition →Other studies you can explore
All current studies →
RecruitingA Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight Without Type 2 DiabetesSarniaCheck availability →
RecruitingA Study of Elecoglipron in Participants With Obesity or Overweight With or Without T2DMToronto · Montreal · VictoriaCheck availability →
RecruitingStudy for People With Excess Body Weight and Knee OsteoarthritisMontrealCheck availability →




